Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation

Mohamed Abdel-Mohsen, Leonard Chavez, Ravi Tandon, Glen M. Chew, Xutao Deng, Ali Danesh, Sheila Keating, Marion Lanteri, Michael L. Samuels, Rebecca Hoh, Jonah Sacha, Philip J. Norris, Toshiro Niki, Cecilia M. Shikuma, Mitsuomi Hirashima, Steven G. Deeks, Lishomwa C. Ndhlovu, Satish K. Pillai

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Identifying host immune determinants governing HIV transcription, latency and infectivity in vivo is critical to developing an HIV cure. Based on our recent finding that the host factor p21 regulates HIV transcription during antiretroviral therapy (ART), and published data demonstrating that the human carbohydrate-binding immunomodulatory protein galectin-9 regulates p21, we hypothesized that galectin-9 modulates HIV transcription. We report that the administration of a recombinant, stable form of galectin-9 (rGal-9) potently reverses HIV latency in vitro in the J-Lat HIV latency model. Furthermore, rGal-9 reverses HIV latency ex vivo in primary CD4+ T cells from HIV-infected, ART-suppressed individuals (p = 0.002), more potently than vorinostat (p = 0.02). rGal-9 co-administration with the latency reversal agent "JQ1", a bromodomain inhibitor, exhibits synergistic activity (p

Original languageEnglish (US)
Article numbere1005677
JournalPLoS Pathogens
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Galectins
HIV
human LGALS9 protein
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Abdel-Mohsen, M., Chavez, L., Tandon, R., Chew, G. M., Deng, X., Danesh, A., ... Pillai, S. K. (2016). Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathogens, 12(6), [e1005677]. https://doi.org/10.1371/journal.ppat.1005677

Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. / Abdel-Mohsen, Mohamed; Chavez, Leonard; Tandon, Ravi; Chew, Glen M.; Deng, Xutao; Danesh, Ali; Keating, Sheila; Lanteri, Marion; Samuels, Michael L.; Hoh, Rebecca; Sacha, Jonah; Norris, Philip J.; Niki, Toshiro; Shikuma, Cecilia M.; Hirashima, Mitsuomi; Deeks, Steven G.; Ndhlovu, Lishomwa C.; Pillai, Satish K.

In: PLoS Pathogens, Vol. 12, No. 6, e1005677, 01.06.2016.

Research output: Contribution to journalArticle

Abdel-Mohsen, M, Chavez, L, Tandon, R, Chew, GM, Deng, X, Danesh, A, Keating, S, Lanteri, M, Samuels, ML, Hoh, R, Sacha, J, Norris, PJ, Niki, T, Shikuma, CM, Hirashima, M, Deeks, SG, Ndhlovu, LC & Pillai, SK 2016, 'Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation', PLoS Pathogens, vol. 12, no. 6, e1005677. https://doi.org/10.1371/journal.ppat.1005677
Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A et al. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathogens. 2016 Jun 1;12(6). e1005677. https://doi.org/10.1371/journal.ppat.1005677
Abdel-Mohsen, Mohamed ; Chavez, Leonard ; Tandon, Ravi ; Chew, Glen M. ; Deng, Xutao ; Danesh, Ali ; Keating, Sheila ; Lanteri, Marion ; Samuels, Michael L. ; Hoh, Rebecca ; Sacha, Jonah ; Norris, Philip J. ; Niki, Toshiro ; Shikuma, Cecilia M. ; Hirashima, Mitsuomi ; Deeks, Steven G. ; Ndhlovu, Lishomwa C. ; Pillai, Satish K. / Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. In: PLoS Pathogens. 2016 ; Vol. 12, No. 6.
@article{d14553621a0a4cae8fd09c344f03ffb5,
title = "Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation",
abstract = "Identifying host immune determinants governing HIV transcription, latency and infectivity in vivo is critical to developing an HIV cure. Based on our recent finding that the host factor p21 regulates HIV transcription during antiretroviral therapy (ART), and published data demonstrating that the human carbohydrate-binding immunomodulatory protein galectin-9 regulates p21, we hypothesized that galectin-9 modulates HIV transcription. We report that the administration of a recombinant, stable form of galectin-9 (rGal-9) potently reverses HIV latency in vitro in the J-Lat HIV latency model. Furthermore, rGal-9 reverses HIV latency ex vivo in primary CD4+ T cells from HIV-infected, ART-suppressed individuals (p = 0.002), more potently than vorinostat (p = 0.02). rGal-9 co-administration with the latency reversal agent {"}JQ1{"}, a bromodomain inhibitor, exhibits synergistic activity (p",
author = "Mohamed Abdel-Mohsen and Leonard Chavez and Ravi Tandon and Chew, {Glen M.} and Xutao Deng and Ali Danesh and Sheila Keating and Marion Lanteri and Samuels, {Michael L.} and Rebecca Hoh and Jonah Sacha and Norris, {Philip J.} and Toshiro Niki and Shikuma, {Cecilia M.} and Mitsuomi Hirashima and Deeks, {Steven G.} and Ndhlovu, {Lishomwa C.} and Pillai, {Satish K.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1371/journal.ppat.1005677",
language = "English (US)",
volume = "12",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation

AU - Abdel-Mohsen, Mohamed

AU - Chavez, Leonard

AU - Tandon, Ravi

AU - Chew, Glen M.

AU - Deng, Xutao

AU - Danesh, Ali

AU - Keating, Sheila

AU - Lanteri, Marion

AU - Samuels, Michael L.

AU - Hoh, Rebecca

AU - Sacha, Jonah

AU - Norris, Philip J.

AU - Niki, Toshiro

AU - Shikuma, Cecilia M.

AU - Hirashima, Mitsuomi

AU - Deeks, Steven G.

AU - Ndhlovu, Lishomwa C.

AU - Pillai, Satish K.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Identifying host immune determinants governing HIV transcription, latency and infectivity in vivo is critical to developing an HIV cure. Based on our recent finding that the host factor p21 regulates HIV transcription during antiretroviral therapy (ART), and published data demonstrating that the human carbohydrate-binding immunomodulatory protein galectin-9 regulates p21, we hypothesized that galectin-9 modulates HIV transcription. We report that the administration of a recombinant, stable form of galectin-9 (rGal-9) potently reverses HIV latency in vitro in the J-Lat HIV latency model. Furthermore, rGal-9 reverses HIV latency ex vivo in primary CD4+ T cells from HIV-infected, ART-suppressed individuals (p = 0.002), more potently than vorinostat (p = 0.02). rGal-9 co-administration with the latency reversal agent "JQ1", a bromodomain inhibitor, exhibits synergistic activity (p

AB - Identifying host immune determinants governing HIV transcription, latency and infectivity in vivo is critical to developing an HIV cure. Based on our recent finding that the host factor p21 regulates HIV transcription during antiretroviral therapy (ART), and published data demonstrating that the human carbohydrate-binding immunomodulatory protein galectin-9 regulates p21, we hypothesized that galectin-9 modulates HIV transcription. We report that the administration of a recombinant, stable form of galectin-9 (rGal-9) potently reverses HIV latency in vitro in the J-Lat HIV latency model. Furthermore, rGal-9 reverses HIV latency ex vivo in primary CD4+ T cells from HIV-infected, ART-suppressed individuals (p = 0.002), more potently than vorinostat (p = 0.02). rGal-9 co-administration with the latency reversal agent "JQ1", a bromodomain inhibitor, exhibits synergistic activity (p

UR - http://www.scopus.com/inward/record.url?scp=84978823390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978823390&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1005677

DO - 10.1371/journal.ppat.1005677

M3 - Article

C2 - 27253379

AN - SCOPUS:84978823390

VL - 12

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 6

M1 - e1005677

ER -